- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Epithelial ovarian, fallopian tube or primary peritoneal cancer
- Meeting Date: July 2025
- Public Summary Document (PSD) July 2025 PBAC Meeting – (PDF 1.4MB)
- Public Summary Document (PSD) July 2025 PBAC Meeting – (Word 653KB)
Related Public Summary Documents
- Mirvetuximab soravtansine –November 2025